AstraZeneca offers $10 billion for Rhythm Pharmaceuticals
The pharmaceutical giant's bid for the obesity drugmaker includes milestone payments.
AI-assisted coverage comparison, editor-supervised · How this was made
AstraZeneca offers $10 billion for Rhythm Pharmaceuticals
MediaBias News
Photograph: MediaBias News
What this story says
- AstraZeneca has made a non-binding offer of about $10 billion for Rhythm Pharmaceuticals.
- The offer values Rhythm at approximately $124 per share, including milestone payments.
- Rhythm's shares rose 28% to close at $110.68 following the news.
- The acquisition would be managed through AstraZeneca's rare-disease unit, Alexion.
Who covered it
Percentages are shares of the 5 outlets carrying a published leaning rating. 5 of the 10 outlets we know ran this story carry no rating and are not counted in them. Coverage measured .
Trust
53/100
Craft
87/100
Hype
15/100
10 sources · methodology
AstraZeneca has submitted a non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, a company focused on therapies for rare metabolic diseases and obesity. The proposed deal values Rhythm at about $124 per share, a figure that includes potential milestone payments.
Following the report of the offer, Rhythm's shares experienced a significant increase, closing up 28% at $110.68 on November 4, 2026. This surge gave the company a market capitalization of roughly $7.64 billion. The potential acquisition would be integrated into AstraZeneca's rare-disease business, Alexion.
Disagreement on offer details
While multiple reports state AstraZeneca made an offer of about $10 billion, the specific per-share price varies. Regional Media News, citing sources, reported AstraZeneca offered as much as $134 a share, including milestone payments. The Wall Street Journal, as reported by Reuters and WTVB, stated the offer was $124 per share last month. Dealroom.co and DiarioBitcoin also mentioned milestone payments as part of the proposal.
What the coverage left out
None of the centre or right-rated reports mentioned the U.S. Food and Drug Administration's expansion of the approved use of Rhythm's therapy Imcivree in March 2026, a fact established by the verified claims.
Still developing. We have re-checked which outlets are covering this 1 time, most recently on 5 Nov 2026, 11:00, and will add the sides that appear.
How each side covered it
Our own reading of the reporting listed below, written from the outlets’ articles rather than quoted from them. The reasoning is set out on our methodology page.
Left
0 rated outlets
No outlet rated left has run this story so far. We are still checking, and will say plainly if that does not change.
Centre
4 rated outlets
- The centre-rated reports led with AstraZeneca's $10 billion offer for Rhythm Pharmaceuticals. They highlighted that the bid was non-binding and included milestone payments. These reports also noted the subsequent rise in Rhythm's share price and its market capitalization. The digests mentioned that the acquisition would be pursued through AstraZeneca's rare-disease business, Alexion.
Right
1 rated outlet
- The right-rated report from Regional Media News led with AstraZeneca's $10 billion offer for obesity drugmaker Rhythm, citing sources. It specified that the offer was as much as $134 a share, including milestone achievements. The report also mentioned Rhythm's share price increase and market capitalization, and noted that the acquisition would be pursued through Alexion. It included commentary from Jefferies analyst Michael Leuchten, who called AstraZeneca's approach to acquiring rare disease assets 'entirely sensible'.
Questions about this coverage
- How did the left and right cover AstraZeneca offers $10 billion for Rhythm Pharmaceuticals?
- Of the 5 outlets on this story carrying a published leaning rating, 0% are rated left, 80% are rated centre, 20% are rated right. Those percentages are shares of the rated outlets, not of every outlet that ran it, which was 10. The sections above set out what each side emphasised, in its own terms.
- Is AstraZeneca offers $10 billion for Rhythm Pharmaceuticals left or right?
- Too few of the outlets on this story carry a published leaning rating to say. 5 of them do, and this site does not characterise a field under 12: at that size one newsroom filing moves the share by ten points. The percentages above are the count as it stands.
- Is the coverage of AstraZeneca offers $10 billion for Rhythm Pharmaceuticals biased?
- AstraZeneca offers $10 billion for Rhythm Pharmaceuticals is one event reported by 10 outlets, and this page does not rate the story as biased or unbiased. What it publishes is the spread: which outlets ran it, where named rating organisations place each of them on the spectrum, and what each side chose to lead with. A leaning rating describes an outlet's record over time, not this article, and the two should not be run together.
- Which outlets covered AstraZeneca offers $10 billion for Rhythm Pharmaceuticals?
- 10 that we know of, every one of them listed further up this page with a link to its own report and to what we hold on the publisher. Nothing here is a summary of somebody else's summary: the outlets are named so the original reporting can be read.
- What is AstraZeneca's offer for Rhythm Pharmaceuticals?
- AstraZeneca has made a non-binding offer of about $10 billion to acquire Rhythm Pharmaceuticals. This offer values Rhythm at approximately $124 per share, including potential milestone payments.
- How did Rhythm Pharmaceuticals' shares react to the news?
- Rhythm Pharmaceuticals' shares closed up 28% at $110.68 on November 4, 2026, following the report of AstraZeneca's offer. This increased the company's market capitalization to about $7.64 billion.
- Which of AstraZeneca's businesses would handle the acquisition?
- The acquisition of Rhythm Pharmaceuticals would be managed through AstraZeneca's rare-disease business unit, Alexion. Alexion specializes in treatments for rare diseases and is part of AstraZeneca's strategy to expand in specialty medicines.
Read it at the source
10 outlets, grouped by the leaning a published rating gives them. Every headline links to the original; an underlined outlet name opens our profile of that publisher.
Left
0No outlet in this group ran the story.
Centre
4- AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say (opens Reuters in a new tab)
- AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say (opens Investing.com in a new tab)
Investing.com — is Investing.com biased? Our profile of this outlet
- AstraZeneca made a $10bn offer to buy Rhythm Pharmaceuticals (opens Market Screener in a new tab)
Market Screener — is Market Screener biased? Our profile of this outlet
- AstraZeneca made $10 billion bid for obesity drugmaker Rhythm, WSJ reports (opens WTVB in a new tab)
Right
1Not rated
5- Reports: AstraZeneca makes ~$10B offer for rare-obesity drugmaker Rhythm Pharmaceuticals (opens dealroom.co in a new tab)
dealroom.co — is dealroom.co biased? Our profile of this outlet
- Astra Bids for American Obesity Company (opens privataaffarer.se in a new tab)
privataaffarer.se — is privataaffarer.se biased? Our profile of this outlet
- AstraZeneca Would Have Offered up to $10 Billion for Rhythm (opens DiarioBitcoin in a new tab)
DiarioBitcoin — is DiarioBitcoin biased? Our profile of this outlet
- Astra Zeneca Wants to Buy US Company for 97 Billion Kronor (opens borskollen.se in a new tab)
borskollen.se — is borskollen.se biased? Our profile of this outlet
- Sources: Astra Makes Multi-Billion Bid (opens Dagens industri in a new tab)
Dagens industri — is Dagens industri biased? Our profile of this outlet
How did this read?
About the coverage, not about the story. We do not ask whether you agree with what happened — we have no honest use for that answer.
